Joshi K

Janssen Scientific Affairs, LLC, Titusville, NJ, USA.

13 papers

ArticleKetamine

Real-world evaluation of change in depressive symptoms among patients with treatment-resistant depression treated with esketamine.

Marci CD, Joshi K, Severtson SG +2

ArticleKetamine

Profiles of Medicaid Beneficiaries with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray.

Clemens K, Zhdanava M, Teeple A +6

ArticleKetamine

Assessment of patient-reported depression severity in subpopulation of ESCAPE-TRD study: esketamine nasal spray versus quetiapine extended release for treatment-resistant depression.

Clemens K, Rive B, Joshi K +7

ArticleKetamine

Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression.

Clemens K, Teeple A, Rive B +7

ArticleKetamine

Characteristics of patients with major depressive disorder eligible for and prescribed esketamine, treatment outcomes and physician experiences: a physician and patient survey in the United States.

Jha M, Teeple A, Shepherd J +6

ArticleKetamine

Esketamine Nasal Spray vs Quetiapine Extended-Release: Examining Work Productivity Loss and Related Costs in Patients With Treatment-Resistant Depression.

Clemens K, Teeple A, Zhdanava M +6

ArticleKetamine

Mental Health-Related Disability Days and Costs Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray and Conventional Therapies in the USA.

Jha MK, Zhdanava M, Shah A +4

ArticleKetamine

Health Care Resource Use and Medical Costs Among Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior Initiated on Esketamine Nasal Spray or Traditional Treatments in the United States.

Harding L, Zhdanava M, Teeple A +4

ArticleKetamine

Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States.

Clemens K, Zhdanava M, Teeple A +5

ArticleKetamine

Understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal spray.

Harding L, Zhdanava M, Shah A +5

ArticleKetamine

Barriers to Esketamine Nasal Spray Treatment Among Adults With Treatment-Resistant Depression.

Joshi K, Liberman JN, Parab P +2

ArticleKetamine

Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance.

Teeple A, Zhdanava M, Pilon D +3

ArticleKetamine

Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.

Zhdanava M, Teeple A, Pilon D +3